Search information
Ownership
Exclude Filing Types
MBX Biosciences, Inc. Common Stock
Companies
Tables in SEC filings
Source
December 31, 2023 | ||||||||||||||||
Amortized Cost | Unrealized Gain | Unrealized (Loss) | Estimated Fair Value | |||||||||||||
Government and agency securities | $ | 50,093 | $ | 62 | $ | (2) | $ | 50,153 | ||||||||
Total | $ | 50,093 | $ | 62 | $ | (2) | $ | 50,153 |
September 30, 2024 | ||||
Due in one year or less | $ | 187,620 | ||
Due after one year | — | |||
Total | $ | 187,620 |
September 30, | December 31, | |||||||
2024 | 2023 | |||||||
Compensation and benefits | $ | 1,850 | $ | 1,365 | ||||
Research and development expenses | 3,717 | 903 | ||||||
Other | 185 | 114 | ||||||
Total accrued expenses | $ | 5,752 | $ | 2,382 |
September 30, | December 31, | |||||||
2024 | 2023 | |||||||
Security deposits | 50 | 50 | ||||||
Total other assets | $ | 50 | $ | 50 |
Three months ended September 30, | Change | |||||||||||
2024 | 2023 | $ | ||||||||||
Operating expenses: | ||||||||||||
Research and development | $ | 16,747 | $ | 9,073 | $ | 7,674 | ||||||
General and administrative | 2,865 | 1,872 | 993 | |||||||||
Total operating expenses | 19,612 | 10,945 | 8,667 | |||||||||
Loss from operations | (19,612) | (10,945) | (8,667) | |||||||||
Other income (expense) | ||||||||||||
Interest and other income, net | 1,470 | 783 | 687 | |||||||||
Total other income, net | 1,470 | 783 | 687 | |||||||||
Net loss | $ | (18,142) | $ | (10,162) | $ | (7,980) |